Omada Health(OMDA)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Omada Health demonstrates strong top-line momentum with 42.0% year-over-year revenue growth in 2026Q1, yet the company faces persistent challenges in achieving consistent operating leverage as evidenced by a -6.1% operating margin.
• While the transition to a debt-free balance sheet provides a $211.8 million cash buffer, the long-term outlook remains sensitive to the disruptive impact of GLP-1 weight-loss medications on clinical protocols.
• Investors should monitor whether the company can stabilize its cyclical free cash flow, which swung from a 27.9% margin in 2025Q4 to -15.3% in 2026Q1, to justify its current valuation.